Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

Section Editor Kathleen Pritchard discloses that she serves as a consultant for and receives honoraria from Novartis, Roche, AstraZeneca, and Pfizer. Reviewer “A ” discloses no financial relationships. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. On the basis of disclosed information, all conflicts of interest have been resolved. LEARNING OBJECTIVES After completing this course, the reader will be able to: 1. Describe how PTEN loss, PIK3CA mutations, and AKT dysregulation affect the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling network in human breast cancer. 2. Review the current state of AKT and mTOR inhibitor development, and describe its potential for clinical applications. This article is available for continuing medical education credit at CME.TheOncologist.com.CME The phosphatidylinositol 3-kinase (PI3K)/AKT/mamma-lian target of rapamycin (mTOR) network plays a key reg